Research programme: HDL-related therapeutics - Esperion/University of Michigan
Alternative Names: Paraoxonase research programme - Esperion Therapeutics/University of Michigan; Research programme: dyslipidaemia therapies - Pfizer/University of MichiganLatest Information Update: 30 Apr 2007
At a glance
- Originator University of Michigan
- Developer Esperion Therapeutics; University of Michigan
- Class Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Septic shock
Most Recent Events
- 30 Apr 2007 NTTC project; made disc
- 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
- 01 Feb 2001 Preclinical development for Ischaemic heart disorders in USA (Unknown route)